Literature DB >> 7917985

Skin cancers or premalignant lesions occur in half of high-dose PUVA patients.

L R Lever1, P M Farr.   

Abstract

Although treatment of psoriasis with psoralen and ultraviolet A (PUVA) is associated with a long-term risk of development of cutaneous squamous cell carcinoma (SCC), the role of PUVA alone is not established, as many patients in reported series had also received treatment with other carcinogens, such as superficial X-rays or arsenic. We have recalled and examined 54 of the 63 patients still alive who have had PUVA treatment in our department, and who have been exposed to a cumulative UVA dose greater than 2000J/cm2. None of the patients had been treated with superficial X-rays or arsenicals. Ten patients (19%) had developed SCC, and 25 (46%) had histologically atypical squamous keratoses arising at body sites similar to the carcinomas. The patients with SCC were significantly older at the start of PUVA treatment than those with keratoses alone. None of the 13% of patients without PUVA lentigines had keratoses or SCCs. These results show that high-dose PUVA treatment in the U.K., even when given alone, can frequently result in the development of SCC. Further malignancies are to be expected with continued follow-up of the patients with squamous keratoses. Absence of PUVA lentigines may be a useful indicator of a lower risk of PUVA malignancy.

Entities:  

Mesh:

Year:  1994        PMID: 7917985     DOI: 10.1111/j.1365-2133.1994.tb08494.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

1.  The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida.

Authors:  Mark S Nestor; Matthew B Zarraga
Journal:  J Clin Aesthet Dermatol       Date:  2012-04

Review 2.  Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?

Authors:  B Lindelöf
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

3.  Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.

Authors:  M M Mueller; W Peter; M Mappes; A Huelsen; H Steinbauer; P Boukamp; M Vaccariello; J Garlick; N E Fusenig
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

Review 4.  5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

5.  Identification of potentially cytotoxic lesions induced by UVA photoactivation of DNA 4-thiothymidine in human cells.

Authors:  Olivier Reelfs; Peter Macpherson; Xiaolin Ren; Yao-Zhong Xu; Peter Karran; Antony R Young
Journal:  Nucleic Acids Res       Date:  2011-09-02       Impact factor: 16.971

6.  Arsenic-related Bowen's disease, palmar keratosis, and skin cancer.

Authors:  M Cöl; C Cöl; A Soran; B S Sayli; S Oztürk
Journal:  Environ Health Perspect       Date:  1999-08       Impact factor: 9.031

7.  Dietary intakes of vitamins A, C, and E and risk of melanoma in two cohorts of women.

Authors:  D Feskanich; W C Willett; D J Hunter; G A Colditz
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

8.  Thiothymidine plus low-dose UVA kills hyperproliferative human skin cells independently of their human papilloma virus status.

Authors:  Olivier Reelfs; Yao-Zhong Xu; Andrew Massey; Peter Karran; Alan Storey
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

9.  Evaluation of PUVA-Induced Skin Side Effects in Patients Referred to the Imam Reza Hospital of Mashhad in 2005-2007.

Authors:  Masoud Maleki; Mohammad Javad Yazdanpanah; Hamid Hamidi; Leila Jokar
Journal:  Indian J Dermatol       Date:  2014-03       Impact factor: 1.494

10.  A Perspective on the Use of NB-UVB Phototherapy vs. PUVA Photochemotherapy.

Authors:  Sally H Ibbotson
Journal:  Front Med (Lausanne)       Date:  2018-07-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.